Skip to main content
Clinical Trials/ACTRN12622000135718
ACTRN12622000135718
Not yet recruiting
未知

A study of bone characteristics in paediatric spinal cord disorders

Murdoch Children's Research Institute0 sites30 target enrollmentJanuary 27, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Murdoch Children's Research Institute
Enrollment
30
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 27, 2022
End Date
TBD
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Is between the ages of 0 and 16 at time of SCD diagnosis. If potential participant was diagnosed during this time period, but is still under the age of 18, they may participate in the cross\-sectional part of this study.
  • Spinal cord injury diagnosis classified according to the International Standards for the Neurological Classification of Spinal Cord Injury (ISNCSCI) and American Spinal Cord Injury Association Impairment Scale (AIS) levels A to D
  • Diagnostic ICD codes:
  • \- Relating to traumatic SCD: S12, S17, S22, T06, T08, T09, and T14\.9, including all subcodes.
  • \- Relating to non\-traumatic SCD: B99, G04, G37, G95 I171\.4, L02\.9, and M8000/1\.
  • \- Non\-specific lesion codes for acute paraplegia: G8201, G8203, G8205, G8211, G8213, G8215, G8221, G8223, G8225
  • \- Non\-specific lesion codes for acute tetraplegia: G8231, 8235, G8241, G8243, G8245, G8251, G8253, G8255
  • \- Cauda equina syndrome: G8234
  • Provide a signed and dated informed assent form and has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant’s behalf.

Exclusion Criteria

  • Premorbid neuromuscular condition
  • Known primary bone disorder
  • Prior diagnosis of a neural tube defect i.e., spina bifida
  • Is unable to attend for assessments
  • Inability or unwillingness of participant or legally acceptable representative to give written informed consent.

Outcomes

Primary Outcomes

Not specified

Similar Trials